Floatz logo

Pinatuzumab Vedotin

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

Genentech, Inc.antibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Genentech, Inc.
Phase 1CC

Same molecule, other indications

Pinatuzumab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →